Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
264.80-5.41 (-2.00%)
At close: 4:00PM EDT
264.40 -0.40 (-0.15%)
After hours: 07:21PM EDT
After hours: 07:21PM EDT
| Previous Close | 270.21 |
| Open | 269.38 |
| Bid | 264.20 x 900 |
| Ask | 269.50 x 800 |
| Day's Range | 264.35 - 270.37 |
| 52 Week Range | 223.25 - 468.55 |
| Volume | 873,344 |
| Avg. Volume | 982,093 |
| Market Cap | 39.867B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 13.73 |
| EPS (TTM) | 19.29 |
| Earnings Date | Oct. 19, 2021 - Oct. 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 417.70 |
- Motley Fool
3 Big Problems With Biogen's Q3 Results
Biogen (NASDAQ: BIIB) announced its third-quarter results on Wednesday. It's certainly true that Biogen did top analysts' estimates on both the top and bottom lines. Instead, there were three big problems with Biogen's Q3 results.
- Motley Fool
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis. Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually.
© 2021 Verizon Media. All rights reserved.
